Hormone Therapy and GLP-1s in 2026: New Data Says Midlife Women May Lose More Weight With Both

Researchers led by Dr. Regina Castaneda of Mayo Clinic Florida analyzed records from nearly 2,400 women taking semaglutide (the ingredient in Wegovy and Ozempic) and nearly 1,500 women taking tirzepatide (Zepbound and Mounjaro). All were over age 45 with a BMI above 27 — in other words, exactly the population most likely to be fighting midlife weight gain. The team compared women who were using menopause hormone therapy with women who weren't, according to The Menopause Society's announcement.

The results split by medication. Among women on semaglutide, hormone therapy users had significantly greater weight loss — and kept it off over time. Among women on tirzepatide, hormone therapy users initially lost more weight, but by the end of the study the difference was no longer statistically significant. The researchers describe this as the first known large real-world cohort of midlife women treated for overweight or obesity, and the findings will be presented at the society's meeting in San Diego, October 20-24, 2026.

Earlier this year, a smaller Mayo Clinic study published in The Lancet Obstetrics, Gynaecology, & Women's Health looked at 120 patients who had been on tirzepatide for at least 12 months. Postmenopausal women who combined it with hormone therapy lost about 35% more weight than women taking tirzepatide alone, according to Mayo Clinic's report on the study.

Why might estrogen matter? The study authors point to preclinical research suggesting estrogen may enhance the effects of GLP-1 medications. There are also indirect explanations: treating hot flashes and night sweats improves sleep and quality of life, which makes it easier to stay consistent with the nutrition and movement habits that drive results on a GLP-1 program.

Both studies are observational, not randomized trials — so they can show an association, not prove cause and effect. As senior author Dr. Maria Daniela Hurtado Andrade put it, "Because this was not a randomized trial, we cannot say hormone therapy caused additional weight loss." Women who choose hormone therapy may already be more engaged with their health, sleep better, or exercise more.

Dr. Castaneda has been equally direct about the new data: it's too early to draw firm conclusions, and weight loss is not an approved reason to start menopause hormone therapy. Hormone therapy is prescribed to treat menopause symptoms — hot flashes, night sweats, sleep disruption, genitourinary symptoms — and any weight benefit observed in these studies came in women who were appropriate candidates for it anyway. The Mayo team is planning a randomized trial to test the question properly.

Menopause changes the math of weight management. Declining estrogen shifts fat storage toward the abdomen, muscle mass declines faster, and sleep disruption raises appetite and cravings. Many women report that strategies that worked at 35 stop working at 50. That's part of why GLP-1 medications have become such an important tool for midlife women: they address appetite and biology rather than relying on willpower alone.

What this new research adds is a reminder that weight in midlife isn't a single-lever problem. Hormones, sleep, muscle, and metabolism interact — and a treatment plan that looks at the whole picture may outperform one that doesn't. If you've hit a plateau on semaglutide or tirzepatide and you're also dealing with untreated menopause symptoms, those two facts might be related.

Hormone therapy isn't for everyone. It's generally most appropriate for women within about 10 years of menopause who have bothersome symptoms, and it's typically avoided in women with a history of breast cancer, blood clots, stroke, or certain liver conditions. Common side effects can include breast tenderness, bloating, and irregular bleeding, especially early on. The decision involves weighing your symptoms, age, health history, and personal risk factors with a licensed provider — not something to start because of a single study.

The same goes for GLP-1 medications, which commonly cause nausea, constipation, and other digestive side effects (most manageable, especially with anti-nausea support), and which require screening for conditions like a personal or family history of medullary thyroid cancer. The takeaway from this research isn't "add hormones to lose weight" — it's that midlife women deserve a weight loss plan built around midlife biology.

JoeyMed treats both sides of this equation. Our licensed providers offer medical weight loss programs built around GLP-1 medications like semaglutide and tirzepatide — including higher-dose options like Tirz HD — with dosing, side effect management, and check-ins handled online. And through our wellness and hormone services, you can discuss whether your menopause symptoms deserve treatment in their own right.

If you're a woman in your 40s, 50s, or 60s and weight loss has felt harder than it should, a short online visit can help you understand your options. Your provider can review whether a GLP-1 is right for you, whether your symptoms suggest a hormonal conversation is worth having, and how to build a plan that treats your biology — not just the number on the scale.